Its important to follow the dosing schedule provided by your healthcare provider, as they can help track the progress of the treatment plan
Dose-dependent ameliorative effects of quercetin and l-Carnitine against atrazine-induced reproductive toxicity in adult male Albino rats
Autoimmune thyroid disorders: the Mediterranean diet as a protective choice
Even among patients with diabetes, where the clinical case for continued treatment was strongest, 46.5 percent stopped within 12 months
If symptoms persist or worsen, antibiotics may be necessary
In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)